Effect of dual residual risk of cholesterol and inflammation on all-cause mortality in patients with cardiovascular disease
Authors' conclusion
Risks of residual cholesterol and residual inflammation remain in patients with CVD after receiving statins, and their combined effect significantly increases the risk of all-cause mortality. Here, this increased risk was dependent on statin compliance, LDL-C reduction, SMART 2 risk score, and blood pressure and blood glucose control.
Study context
- Population
- Patients with a cardiovascular disease (CVD) history who first took statins between 1 January 2010 and 31 December 2017, Kailuan Study; mean age 63.69 ± 8.41 years, 86.78% men377 deaths
- Participants
- 3,509 patients
- Exposure
- Residual inflammatory, cholesterol, or combined risk vs no residual risk
- Outcome
- All-cause mortality
- Follow-up
- 6.10 years
Methodological detailsreal-world population, Kailuan Study
- Real-world population
- Kailuan Study
Main finding
As reported in the abstract
6.10 years
Each group vs no residual riskHazard ratio (95% CI)
RIR
1.63(1.05–2.52)
RCR
1.37(0.98–1.90)
RCIR
1.75(1.25–2.46)
Observational data: associations, not effects.
Further findings
All-cause mortality, residual cholesterol and inflammatory risk (RCIR) vs reference, in subgroups
- Moderate or low statin compliance
- 1.66-fold
- Lower percentage of low-density lipoprotein cholesterol (LDL-C) decline
- 2.08-fold
- High SMART 2 risk score
- 1.69-fold
- Uncontrolled blood pressure
- 2.04-fold
- Uncontrolled blood glucose
- 2.05-fold
- Stratified analysis
Original publication
Effect of dual residual risk of cholesterol and inflammation on all-cause mortality in patients with cardiovascular disease. Cardiovasc Diabetol. Published 24 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →